Bio News
SML Genetree has partnered with ResInnova, a U.S. CLIA-certified laboratory, to accelerate its entry into the U.S. molecular diagnostics market, which began in May 2026. The two companies formalized the partnership on July 30 and will collaborate to supply SML Genetree’s molecular diagnostics product line, NamuPlex™, to the U.S. LDT market. Through this partnership, SML Genetree plans to expand its partnerships in the United States and strengthen its position as a global molecular diagnostics company.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
